Towards evidence-based response criteria for cancer immunotherapy Wednesday, July 19, 2023 Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Describe here are the next steps required to test its validity and how novel approaches for response criteria might be developed and included. Garralda E, Laurie SA, Seymour L, de Vries EGE. Towards evidence-based response criteria for cancer immunotherapy. Nat Commun. 14: 3001, 2023. https://www.nature.com/articles/s41467-023-38837-3
